Cognitive dysfunction in the patient with antiphospholipid antibodies: considerations for cause and treatment

Curr Rheumatol Rep. 2006 Apr;8(2):89-94. doi: 10.1007/s11926-006-0047-x.

Abstract

The evidence supporting a causal relationship between antiphospholipid (aPL) antibodies and cognitive dysfunction is very limited despite a general impression that one exists. Patients with aPL antibodies may complain of cognitive difficulties in their everyday lives, forcing the clinician to examine this issue. As with other non-thrombotic antiphospholipid syndrome (APS) manifestations, cognitive dysfunction in this population should be approached as a diagnosis of exclusion. The complexity in diagnosing and treating various manifestations of rheumatic disease holds true for identifying and addressing cognitive decline in these patients.

Publication types

  • Review

MeSH terms

  • Antibodies, Antiphospholipid / immunology*
  • Cognition Disorders / immunology*
  • Cognition Disorders / therapy
  • Cognitive Behavioral Therapy / methods*
  • Humans
  • Treatment Outcome

Substances

  • Antibodies, Antiphospholipid